ConductScience.org, home

Paper36960932

Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment.

Guo Z and 3 others. Small Methods, 2023. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment. Papers, record 36960932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36960932

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment.
PubMed
Journal
Small Methods
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
2.36
iCite
Revised in PubMed
2024-09-29
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guo ZZhongyuan
2Zhu ATAudrey T
3Fang RHRonnie H
4Zhang LLiangfanghttps://orcid.org/0000-0003-0637-0654

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
NanoparticlesMajor topic
Humans
Phototherapy
Immunotherapy
Drug Delivery Systems

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R21 AI159492NIAID NIH HHSUnited StatesR21AI159492PubMed and NIH
R21AI159492NIH HHSUnited StatesR21AI159492PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References225

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135735086Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer.Adv Healthc Mater2022https://conductscience.org/library/papers/35735086PubMed
228187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
332271563Reprogramming Tumor Microenvironment with Photothermal Therapy.Bioconjug Chem2020https://conductscience.org/library/papers/32271563PubMed
434504391Perfluorocarbon nanomaterials for photodynamic therapy.Curr Opin Colloid Interface Sci2021https://conductscience.org/library/papers/34504391PubMed
534611678Near infrared photothermal conversion materials: mechanism, preparation, and photothermal cancer therapy applications.J Mater Chem B2021https://conductscience.org/library/papers/34611678PubMed
636242941Red blood cell membrane nanoparticles for tumor phototherapy.Colloids Surf B Biointerfaces2022https://conductscience.org/library/papers/36242941PubMed
729113417Porphyrin photosensitizers in photodynamic therapy and its applications.Oncotarget2017https://conductscience.org/library/papers/29113417PubMed
830444351Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth.ACS Nano2018https://conductscience.org/library/papers/30444351PubMed
925615236Modulating antibacterial immunity via bacterial membrane-coated nanoparticles.Nano Lett2015https://conductscience.org/library/papers/25615236PubMed
1033290263Enhancer-bound Nrf2 licenses HIF-1α transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells.Aging (Albany NY)2020https://conductscience.org/library/papers/33290263PubMed
1133824489Emerging concepts in the science of vaccine adjuvants.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33824489PubMed
1227532320Carbon-Dot-Decorated Carbon Nitride Nanoparticles for Enhanced Photodynamic Therapy against Hypoxic Tumor via Water Splitting.ACS Nano2016https://conductscience.org/library/papers/27532320PubMed
1332979727Alleviating tumor hypoxia with perfluorocarbon-based oxygen carriers.Curr Opin Pharmacol2020https://conductscience.org/library/papers/32979727PubMed
1431202726Light triggered oxygen-affording engines for repeated hypoxia-resistant photodynamic therapy.J Control Release2019https://conductscience.org/library/papers/31202726PubMed
1536442438Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy.Biomaterials2023https://conductscience.org/library/papers/36442438PubMed
1631847487Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer.Cells2019https://conductscience.org/library/papers/31847487PubMed
1725049431Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.J Immunol2014https://conductscience.org/library/papers/25049431PubMed
1835967738Stem cell membrane-camouflaged targeted delivery system in tumor.Mater Today Bio2022https://conductscience.org/library/papers/35967738PubMed
1917101732Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.J Exp Med2006https://conductscience.org/library/papers/17101732PubMed
2025082815CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Cancer Res2014https://conductscience.org/library/papers/25082815PubMed

See all 225 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42233111Assessment of Anticancer Effect of Rhodium Nanoparticle-based Photodynamic Therapy via Protein-Protein Interaction Network Analysis.J Lasers Med Sci2026https://conductscience.org/library/papers/42233111PubMed
42077816Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale Adv2026https://conductscience.org/library/papers/42077816PubMed
41948173Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer.Int J Nanomedicine2026https://conductscience.org/library/papers/41948173PubMed
41939214Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma.Int J Nanomedicine2026https://conductscience.org/library/papers/41939214PubMed
41646191A mini-review: photodynamic therapy-induced immune activation.Front Pharmacol2026https://conductscience.org/library/papers/41646191PubMed
41366426Macrophage membrane-coated nanoparticles in inflammatory diseases: from bioinspired design to translational potential.J Nanobiotechnology2025https://conductscience.org/library/papers/41366426PubMed
41334375Barrier-disrupting microneedle technology: Overcoming physical, physiological, and pathological skin defenses to enhance therapeutic efficacy.Bioact Mater2026https://conductscience.org/library/papers/41334375PubMed
40878947New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).Int J Mol Med2025https://conductscience.org/library/papers/40878947PubMed
40788347Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer.Drug Deliv Transl Res2025https://conductscience.org/library/papers/40788347PubMed
40470111Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics.Int J Nanomedicine2025https://conductscience.org/library/papers/40470111PubMed
40264819Illuminating Hope for Tumors: The Progress of Light-Activated Nanomaterials in Skin Cancer.Int J Nanomedicine2025https://conductscience.org/library/papers/40264819PubMed
40058873Diverse nanoparticles deliver mRNA to enhance tumor immunotherapy.BMB Rep2025https://conductscience.org/library/papers/40058873PubMed
40027868Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy.Int J Nanomedicine2025https://conductscience.org/library/papers/40027868PubMed
39655738Immunogenic cell death: A new strategy to enhancing cancer immunotherapy.Hum Vaccin Immunother2024https://conductscience.org/library/papers/39655738PubMed
39128942Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39128942PubMed
39078330Magnetic Cell Targeting for Cardiovascular Tissue Engineering.Tissue Eng Part B Rev2025https://conductscience.org/library/papers/39078330PubMed
38764446A genetically engineered neuronal membrane-based nanotoxoid elicits protective immunity against neurotoxins.Bioact Mater2024https://conductscience.org/library/papers/38764446PubMed
38407670Theranostics: a multifaceted approach utilizing nano-biomaterials.Discov Nano2024https://conductscience.org/library/papers/38407670PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36960932

GET https://conductscience.org/api/papers/v1/36960932/references?page=2